Therapeutic vaccines against infectious diseases

Current Opinion in Microbiology

Volumn 6, Issue 5, 2003, Pages 462-471

  Moingeon, Philippe ^a,b   Almond, Jeffrey ^a   De Wilde, Michel ^a  

^a SANOFI PASTEUR   (France)

^b Stallergenes SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BCG VACCINE; CANDIDA ALBICANS VACCINE; ESCHERICHIA COLI VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LEISHMANIA VACCINE; MALARIA VACCINE; MEMBRANE ANTIGEN; SMALLPOX VACCINE;

ANTHRAX; CANDIDA ALBICANS; CELLULAR IMMUNITY; CHLAMYDOPHILA PNEUMONIAE; DRUG EFFICACY; ESCHERICHIA COLI; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HOSPITAL INFECTION; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNOTHERAPY; INFECTION; LEISHMANIA MAJOR; MYCOBACTERIUM TUBERCULOSIS; PASSIVE IMMUNIZATION; PLASMODIUM FALCIPARUM; PRION; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SEPSIS; SEPTIC SHOCK; SMALLPOX; STREPTOCOCCUS MUTANS; WART VIRUS;

ANTHRAX; CANDIDA; CANDIDA ALBICANS; CHLAMYDOPHILA; CHLAMYDOPHILA PNEUMONIAE; ESCHERICHIA COLI; HELICOBACTER; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPES; LEISHMANIA MAJOR; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; PLASMODIUM FALCIPARUM; PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS; SIMPLEXVIRUS; STREPTOCOCCUS; STREPTOCOCCUS MUTANS; VARIOLA VIRUS;

EID: 0242323598     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2003.08.002     Document Type: Review

References (66)

1. Seder RA, Hill A: Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406:793-798.
2. Vandepapelière P: Therapeutic vaccination against chronic viral infection. Lancet Infect Dis 2002, 2:353-367. A thorough review focused on HBV, HPV, HSV and HIV.
3. Sela M, Arnon R, Schechter B: Therapeutic vaccines: realities of today and hopes for the future. Drug Discov Today 2002, 7:664-673.
4. Moingeon P: Strategies for designing vaccines eliciting Th1 responses in humans. J Biotechnol 2002, 98:189-198.
5. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645-1653. The first large-scale clinical study demonstrating the efficacy of an HPV-16 VLP vaccine in reducing the incidence of HPV16 infection and of related CIN.
6. Frazer I: Vaccines for papilloma infection. Virus Res 2002, 89:271-274.
7. + T cell responses elicited during vaccination differs significantly from responses elicited during natural acute or chronic infection.
8. Kaufmann S: How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001, 1:20-30.
9. Zhang L, Yu W, He YJ, Caffrey R, Dalmasso E, Fu S, Pham T, Mei J, Ho J, Zhang W et al.: Contribution of human α defensin 1, 2 and 3 to the anti-HIV1 activity of CD8 antiviral factor. Science 2002, 298:995-998.
10. + regulatory T cells control Leishmania major persistence and immunity. Nature 2002, 420:502-505. Important study establishing in mice a role for regulatory T cells in facilitating the persistence of Leishmania major in the dermis after healing. This raises the issue of designing vaccines targeting such regulatory T cells.
11. + T cell proliferation is coupled to perforin expression and is maintained in non-progressors. Nat Immunol 2002, 3:1061-1068.
12. Pardoll DM: Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002, 2:227-238.
13. Srivastava P, Amato R: Heat shock proteins: the Swiss army knife vaccines against cancers and infectious agents. Vaccine 2001, 19:2590-2597.
14. Oglesbee MJ, Pratt M, Carsillo T: Role for heat shock proteins in the immune response to measles virus infection. Viral Immunol 2002, 15:399-416. In this study, hyperthermic treatment to elevate brain levels of HSPs promoted cell-mediated viral clearance in mice with persistent measles infection. This illustrates the power of HSPs as natural adjuvants and as cross-priming agents in a therapeutic setting.
15. Moore C, John M, James I, Christiansen F, Witt C, Mallal S: Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296:1349-1442.
16. Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL: Virus subversion of immunity: a structural perspective. Curr Opin Immunol 2001, 13:442-450.
17. + T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001, 13:483-488.
18. Peters BS: The basis for HIV immunotherapeutic vaccines. Vaccine 2002, 20:688-705.
19. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, Deschenes GR, Ramanathan M Jr, Barsoum S, Vanderhoeven J et al.: Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002, 186:634-643. A clinical study in patients treated with HAART early after infection with HIV. After treatment discontinuation, the magnitude and dynamics of virus rebound was found to be similar in unvaccinated subjects and in patients receiving a vaccine (canarypox ALVAC env-gag-pol-nef) together with the recombinant envelope protein rgp 160. This study illustrates the difficulty of combining chemotherapy and immunotherapy as well as why this is such an interesting angle for research.
20. Oxenius A, Price D, Gunthard H, Dawson S, Fagard C, Perrin L, Fisher M, Weber R, Plana M, Garcia F et al.: Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002, 99:13747-13752.
21. + T cell responses. This study raises interest in associating HAART and therapeutic vaccination.
22. Lu W, Wu X, Lu Y, Guo W, Andrieu J-M: Therapeutic dendritic cell vaccine for simian AIDS. Nat Med 2003, 9:27-32.
23. Perrin L: Therapeutic vaccination in primary HIV infection, the Quest trial. Vaccine 2002, 20:2004-2006.
24. Altfeld M, Allen T, Yu X, Johnston M, Agrawal D, Korber B, Montefiori D, O'Connor D, Davis B, Lee P et al.: HIV-1 super infection despite broad T-cell responses containing replication of the primary virus. Nature 2002, 420:434-436.
25. + T cell proliferative response in chronic hepatitis B carriers. Vaccine 2002, 20:3598-3612.
26. + cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection. Mol Immunol 2001, 38:467-473.
27. Guha C, Sha SJ, Ghosh S, Lee SW, Roy-Chowdhury N, Roy-Chowdhury H: Molecular therapies for viral hepatitis. BioDrugs 2003, 17:81-91.
28. Thermet A, Rollier C, Zoulim F, Trepo C, Cova L: Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. Vaccine 2003, 21:659-662.
29. Michel M-L, Pol S, Brechot C, Tiollais P: Immunotherapy of chronic hepatitis B by anti-H BV vaccine: from present to future. Vaccine 2001, 19:2395-2399.
30. Engler OB, Dai WJ, Sette A, Hunziker IP, Reichen J, Pichler WJ, Cerny A: Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol Immunol 2001, 38:457-465.
31. Wang J, Zhu Q, Zhang T, Yu H: A pilot study on the combined therapy of granulocyte-macrophage colony-stimulating factor and hepatitis B vaccine on chronic hepatitis B virus carrier children. Chin Med J 2002, 115:1824-1828.
32. Pancholi P, Lee D-H, Liu Q, Tackney C, Taylor P, Perkus M, Andrus L, Brotman B, Prince AM: DNA prime-canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 2001, 33:448-454.
33. Foy E, Li K, Wang C, Sumpter R, Ikeda M, Lemon S, Gale M: Regulation of interferon regulatory factor 3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148. A very interesting study demonstrating a role for the HCV N53/4A serine protease in blocking the activity of interferon regulatory factor 3. This finding might help with the design of small-molecule drugs inhibiting viral replication as well as new candidate vaccines based on a live attenuated virus.
34. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, Feinstone SM: Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002, 76:6586-6595.
35. Polakos N, Drane D, Cox J, Ng P, Selby M, Chien D, O'Hagan D, Houghton M, Paliard X: Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a non-classical ISCOM vaccine. J Immunol 2001, 166:3589-3598.
36. Edwards SL, Margetts MB, Hocking DM, Maloney MB, Rothel LJ, Webb EA: Design of a candidate recombinant therapeutic vaccine for cervical cancer. Res Dev Biotech Bioeng 1998, 1:343-356.
37. Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC: Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996, 14:1485-1494.
38. De Jong A, O'Neill T, Khan A, Kwappenberg KM, Chisholm S, Whittle N, Dobson J, Jack L, St Clair Roberts J, Offringa R et al.: Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16L2E7E6 fusion protein vaccine. Vaccine 2002, 20:3456-3464.
39. Thompson HS, Davies ML, Holding F, Fallon R, Mann A, O'Neill T, St Clair Roberts J: Phase I safety and antigenicity of TA-GW: a recombinant HPV6L2E7 vaccine for the treatment of genital warts. Vaccine 1999, 17:40-49.
40. Klencke B, Matijevic M, Urban R, Lathey J, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T et al.: Encapsulated plasmid DNA treatment for human papillomavirus 16 associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 2002, 8:1028-1037. Phase-I dose-escalation study demonstrating the safety of plasmid DNA encapsulated in microspheres. The vaccine targeted HLA-A2 T cell epitopes from HPV 16 E6 and E7, and elicited immune responses and potentially histologically provable clinical responses in patients with anal dysplasia.
41. Zwaveling S, Ferreira Mota S, Nouta J, Johnson M, Lipford G, Offringa R, van der Burg S, Melief C: Established human-papillomavirus-type-16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002, 169:350-358.
42. Palefsky JM, Goldstone SE, Winnet M, Siegel MI, Neefe JR: HspE7 treatment of anal dysplasia: results of an open label trial of HspE7 and comparison with a prior controlled trial of low dose HspE7. Abstract H-1660, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): 2001 December 16-19; Chicago.
43. Samady L, Costigliola E, MacCormac L, McGrath Y, Cleverley S, Lilley C, Smith J, Latchman D, Chain B, Coffin RS: Deletion of the virion host shutoff protein (vhs) from herpes simplex virus relieves the viral block to dendritic cell activation: potential of vhs-HSV vectors for dendritic-cell-mediated immunotherapy. J Virol 2003, 77:3768-3776.
44. + cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10APK. Vaccine 2002, 20:2796-2807.
45. Harrison CJ, Miller RL, Bernstein DI: Reduction of recurrent HSV disease using Imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001, 19:1820-1826.
46. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M et al.: Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347:1652-1659.
47. Lowrie DB, Tascon R, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, Colston MJ, Hewinson RG, Moelling K, Silva C: Therapy of tuberculosis in mice by DNA vaccination. Nature 1999, 400:269-271.
48. Mwinga A, Nurin A, Ngwira B, Chintu C, Warndorff D, Fine P, Darbyshire J, Zumia A: Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002, 360:1055-1061.
49. Prinz C, Hafsi N, Voland P: Helicobacterpylori virulence factors and the host immune response: implications for therapeutic vaccination. Trends Microbiol 2003, 11:134-138.
50. Koga T, Oho T, Shimazaki Y, Nakano Y: Immunization against dental caries. Vaccine 2002, 20:2027-2044. Comprehensive review of active and passive immunotherapeutic approaches that have been conducted in animals or in humans to treat infections associated with dental caries.
51. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R et al.: Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002, 346:491-499.
52. Cohen J: The immunopathogenesis of sepsis. Nature 2002, 420:885-890.
53. Igietseme JU, Black CM, Caldwell HD: Chlamydia vaccines. Strategies and status. BioDrugs 2002, 16:19-35.
54. Bauer HW, Rahlfs VW, Lauener PA, Blebmann GS: Prevention of recurrent urinary tract infections with immunoactive E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents 2002, 19:451-456.
55. Breman J, Henderson DA: Diagnosis and management of smallpox. N Engl J Med 2002, 346:1300-1308.
56. Sellman BR, Mourez M, Collier R: Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 2002, 292:695-697. A dominant-negative mutant of the protective antigen (PA) toxin of Bacillus anthracis has been produced that can elicit cross-neutralizing antibodies and can also act therapeutically by preventing the assembly of the native toxin molecule.
57. Xu Z, Wei L, Wang L, Wang H, Jiang S: The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization. Biochem Biophys Res Com 2002, 298:552-558.
58. Nelson RP, Ballow M: Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors and antibodies. J Allergy Clin Immunol 2003, 111:S720-S732.
59. Vujovic O, Mills J: Preventive and therapeutic strategies for respiratory syncytial virus infection. Curr Opin Pharmacol 2001, 1:497-503.
60. Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, Ballou WR, Holland CA, Kester K, Voss G et al.: A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS/SBAS2 in semi-immune adults in the Gambia. Am J Trop Med Hyg 1999, 61:865-868.
61. Skelly YA, Coler RN, Brannon M, Strombery E, Greeson K, Crane RT, Compos-Netto A, Reed SG: Protective efficacy of a tandemly linked multi-subunit recombinant leishmanial vaccine (Leish IIIf) formulated in MPL adjuvant. Vaccine 2002, 20:3292-3303.
62. Magliani W, Conti S, Cassone A, De Bernadis F, Polonelli L: New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol Med 2002, 8:121-126.
63. Heppner FL, Musahl C, Arnighi I, Klein MA, Reilicke T, Oesch B, Zinkernagel RM, Kalinke U, Aguzzi A: Prevention of scrape pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001, 294:178-182.
64. Hornef MW, Wick MJ, Rhen M, Normark S: Bacterial strategies for overcoming host innate and adaptive immune responses. Nat Immunol 2002, 3:1033-1039.
65. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringeri A, Santagostino E, Rappaport J et al.: Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998, 95:3851-3856.
66. Hengel H, Masihi KN: Combinatorial immunotherapies for infectious diseases. Int Immunopharmacol 2003, 458:1-9.